Patient with retrorectal necrotizing fasciitis forgoes colostomy in favor of treatment with MiroDerm

Large indurated area on buttock and perineum. Very tender. No drainage.

CT scan showed a large retrorectal necrotizing infection. Visible gas bubbles were consistent with a gas-forming organism.

Retrorectal necrotizing fasciitis

The initial surgeon carried the incision onto the anoderm. The external sphincter was exposed and palpable. The wound crossed the midline and the tip of the coccyx was felt at the apex. The debrided wound size was 10L x 15W x 10D cm.

The wound underwent sharp debridement, cleansing with a Pulsavac® device, and
application of a Negative Pressure Suction Device (NPSD) for seven days.

MIRODERM FENESTRATED DAY 1
Wound size: 8L x 10W x 6.5D cm
Initial MiroDerm Fenestrated application (8 x 15 cm) occurred seven days post initial debridement. An anoplasty was performed, and VersaFoam® was placed over the MiroDerm Fenestrated.

MIRODERM FENESTRATED DAY 7
Wound size: 8L x 6W x 5D cm
Initial MiroDerm Fenestrated product had incorporated into wound, with a marked reduction in wound depth. MiroDerm Fenestrated (5 x 5 cm) was applied for the second time, and anoplasty was
repeated to facilitate Negative Pressure Wound Therapy (NPWT).

MIRODERM FENESTRATED DAY 12
Wound size: 7.5L x 6W x 4D cm
The wound volume reduced by 65% since Day 1. MiroDerm Fenestrated was still present in the wound, and the remaining product was re-sutured. No additional MiroDerm Fenestrated was placed at this time.

MIRODERM FENESTRATED DAY 19
Wound size: 5L x 3W x 2D cm
The wound volume reduced by more than 90% since Day 1. The remaining MiroDerm Fenestrated had integrated into granulation tissue. MiroDerm Fenestrated (3 x 7 cm) was placed for a third time.

MIRODERM FENESTRATED DAY 27
Wound size: 5L x 2W x 2D cm
Three days after the third MiroDerm Fenestrated application, a nurse accidentally removed the NPSD and MiroDerm Fenestrated, necessitating a return to the OR on Day 27 for a fourth MiroDerm Fenestrated application (3 x 7 cm).

MIRODERM FENESTRATED DAY 31
Wound size: 5L x 2W x 1D cm
NPWT was discontinued.

MIRODERM FENESTRATED DAY 35
Wound size: 3.5L x 1W x 1D cm
Post-closure wound size: 2L x 1W x .5D cm
Patient was discharged.

The patient was discharged 35 days after the first MiroDerm Fenestrated application, with intact anoplasty and good sphincter control. The remaining wound was dressed with hydrogel and bio-occlusive dressing.

Due to its size and location on the anoderm, this wound would classically be treated with a diverting colostomy^1,2. After discussing risks and benefits, the patient opted to be placed on an elemental diet and proceed with MiroDerm Fenestrated and NPWT.

Anoplasty and creative dressings with skin glue and DuoDERM® were required to maintain a wound
NPSD seal around the anus. Low intensity, continuous NPWT was performed with suction at 75 mmHg after placing the MiroDerm Fenestrated. Suction was reduced to control exudate rather than promote granulation tissue.

The patient healed in a remarkable amount of time and likely avoided at least two major debilitating surgeries, as well as the emotional and physical impact of a colostomy for 3-6 months. The
accelerated healing observed with MiroDerm Fenestrated is likely the result of Reprise
Biomedical’s unique perfusion decellularization technology, which retains a 3-dimensional
extracellular matrix that includes the vasculature.

 

The experience depicted in this case study may not be representative of all potential clinical outcomes. MiroDerm Fenestrated results may vary by patient. Further study is necessary to determine the benefit of MiroDerm Fenestrated in a variety of wound applications.
1. Wong CH, et al. Necrotizing fasciitis: clinical presentation, microbiology and determinants of mortality. J Bone Joint Surg Am. 2003. 85a(8):1454-60.
2. McHenry, et al. Determinants of mortality for necrotizing soft-tissue infections. Ann Surg. 1995. 221(5):558-565.
MiroDerm Biologic Wound Matrix (Fenestrated and Fenestrated Plus) is indicated for the management of wounds, including: partial and full-thickness wounds; pressure ulcers; venous ulcers; chronic vascular ulcers; diabetic ulcers; tunneled, undermined wounds; trauma wounds (abrasion, lacerations, second-degree burns, skin tears); drainage wounds; and surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence).
CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.
Refer to the Instructions for Use for a complete listing of the indications, contraindications, warnings and precautions. Information in this material is not a substitute for the product Instructions for Use.
Reprise Biomedical and MiroDerm are trademarks or registered trademarks of Reprise Biomedical or its affiliates, in the U.S. and/or other countries. All other trademarks are property of their respective owners. ©2020 Reprise Biomedical. All Rights Reserved. SM-00042 Rev. D 07/20